News & Comments
Exelixis: The European Commission Approves Cabometix for First Line Treatment of Poor-Risk Advanced Renal Cell Carcinoma
Exelixis (EXEL) announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX®(cabozantinib) 20 mg, 40 mg and 60 mg for the first-line treatment of adults …
An FDA Advisory Committee Voted in Favor of Approving Akcea Therapeutics’ Product, WAYLIVRA, for FCS Syndrome.
Ionis Pharmaceuticals (IONS) and Akcea Therapeutics (AKCA), an affiliate of Ionis Pharmaceuticals, announced that the Advisory Committee of the U.S. Food and Drug Administration’s (FDA) Division …
Today’s Highlights
Rhythm Pharmaceuticals: Treating Obesity Prevents and Reverses Intractable Life-Threatening Diseases
Based in Boston, MA, Rhythm Pharmaceuticals (RYTM) - is a company focused on discovering and developing treatments for rare genetic disorders of …
Cures for Hemophilia A and B? See Also: Why EXEL Was a Loser Yesterday
SPARK THERAPEUTICS, SANGAMO THERAPEUTICS AND SALK INSTITUTE CURING HEMOPHILIA? Hemophilia is an inherited bleeding disorder that causes …
Inspiring News from a Small Firm
Following the news announcing that Amgen’s (AMGN) drug KYPROLIS® (carfilzomib) extended the lives of patients with relapsed or refractory …
Amgen has More Good News. What is Going on with the CRISPR Gene Editing Firms?
A couple of days following the news that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has …
Recent Popular Posts:
Amgen: The FDA Approves Aimovig™. The First Specific Migraine Drug.
The U.S. Food and Drug Administration (FDA) approved Amgen’s (AMGN) new once a month drug Aimovig™ (erenumab-aooe) for the prevention and treatment of migraine in adults. Aimovig is the first and …
Exelixis: The European Commission Approves Cabometix for First Line Treatment of Poor-Risk Advanced Renal Cell Carcinoma
Exelixis (EXEL) announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX®(cabozantinib) 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or …
Amgen: The FDA Approves Aimovig™. The First Specific Migraine Drug.
The U.S. Food and Drug Administration (FDA) approved Amgen’s (AMGN) new once a month drug Aimovig™ (erenumab-aooe) for the prevention and treatment of migraine in adults. Aimovig is the first …
| News & Comments